Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger

Rhea-AI Summary

Sema4 and CM Life Sciences (CMLF) have filed a preliminary proxy statement for their proposed business combination, marking a significant milestone in finalizing the transition of Sema4 into a public company focused on clinical genomics. This filing triggers the SEC review process, with the definitive proxy statement expected to be sent to CMLF shareholders. Key executives express optimism about growth potential and strategic goals for 2021, anticipating shareholder approval by the end of July.

Positive

• Filing of a preliminary proxy statement initiates SEC review, advancing the business combination process.
• Expected shareholder approval for the transition to a public company by end of July.
• Sema4 is positioned as a leader in patient-centered clinical genomics with strong growth potential.

Negative

• None.

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination.

The filing of the preliminary proxy statement initiates the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders. “This is an important milestone and begins the process of transitioning Sema4 into an independent public company and leader in the clinical genomics space. There is tremendous growth potential ahead for the company and we are excited by the opportunities that will be enabled by this transaction,” commented Eli Casdin, Chief Executive Officer of CM Life Sciences.

“As each day goes by, Sema4 grows as a leader in patient-centered genomic and clinical data,” remarked Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “Meanwhile, we continue to be on track to achieve the 2021 financial and strategic goals and importantly build a business that is powered to execute on the long term potential of an AI-powered platform to health system partners, providers and their patients.”

“We look forward to consummating the transaction following SEC review and approval from our shareholders, which is anticipated by the end of July,” said Keith Meister, Chairman of CM Life Sciences.

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

About CM Life Sciences

CM Life Sciences was founded to take advantage of a dynamic life science sector buoyed by innovation yet fragmented, where many companies are under-resourced and under-scaled. Significant and under-appreciated opportunities for consolidation are ready for engagement by a team versed in the trends and themes, and who can bring together the strongest of the new companies and management teams to capitalize on near- and far-term opportunities. For more information, please visit https://cmlifesciencesspac.com/

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Sema4 and CM Life Sciences, including statements regarding the anticipated benefits of the transaction, the a

FAQ

What is the significance of the preliminary proxy statement filed by CMLF?

The preliminary proxy statement signifies the start of the SEC review process necessary for finalizing the business combination with Sema4.

When is the shareholder approval for the CMLF and Sema4 merger expected?

Shareholder approval is anticipated by the end of July.

What are Sema4's strategic goals for 2021?

Sema4 aims to achieve its financial and strategic objectives for 2021, focusing on growth in clinical genomics.

What benefits does Sema4 expect from becoming a public company?

Sema4 expects to enhance its leadership in patient-centered genomics and leverage AI for growth opportunities.